In all, 61 of the 66 patients in the control group who had clinically diagnosed hypersensitivity reaction also had epicutaneous patch-testing results that could be evaluated. Approximately 6% of Caucasians and 2-3% of African Americans carry this allele in the human leukocyte antigen B (HLA-B) gene. © Copyright 2020 - iGene | Levy, I.
Patients receiving this diagnosis stopped taking abacavir immediately and permanently, and they returned to the site as soon as possible for an assessment of the hypersensitivity reaction.All patients with a clinical diagnosis of hypersensitivity to abacavir underwent epicutaneous patch testing 6 to 10 weeks after the onset of the reaction, according to a modification of the method of Phillips et al.The results of patch testing were scored by an expert, independent, clinical-evaluation committee on the basis of digital photographs taken on site with cameras provided for use in the study, as well as other patch-test information. — both in London; GlaxoSmithKline, Greenford, United Kingdom (S.H. Santamaria, V. Molotilov, M. Montroni, J. Moreau, E. Morgan, P. Morlat, G. Moshkovich, M. Moutschen, M. Müller, A. Mutz, L. Naumova, M. Nelson, A. Ocampo, O. Øktedalen, C. Oliveira, P. Ortolani, G. Pagano, M. Partisani, G. Pastore, A. Paula Reis, J. Pedreira Andrade, E. Pedrol, G. Pellizzer, M.J. Pérez Elías, P. Perfezou, P. Perre, S. Pheng Quah, P. Philibert, G. Pialoux, L. Piroth, A. Plettenberg, D. Podzamczer, A. Poggio, J. Portilla, S. Portsmouth, J. Portu Zapirain, L. Potemina, T. Prazuck, L.-J. A positive test result means you have the HLA-B*5701 gene variant and have a higher risk of developing a potentially life-threatening reaction to abacavir. Koopmans, G.J.
Concise summaries and expert physician commentary that busy clinicians need to enhance patient care.The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.NEW! It is known, for example, that mutations in the HLA-B*5701 gene may be partly responsible.
If your test result is positive, you should not take abacavir. Phillips and Hay, receiving consulting fees, lecture fees, and other payments from GlaxoSmithKline; Drs. Screening eliminated immunologically confirmed hypersensitivity reaction (0% in the prospective-screening group vs. 2.7% in the control group, P<0.001), with a negative predictive value of 100% and a positive predictive value of 47.9%. Sprenger, S. Staszewski, M. Stella Mura, A. Streinu-Cercel, G. Sture, L. Sultanov, F. Suter, M. Tarasova, M. Telenti, H. Thaker, F. Tollinchi, O. Tonkikh, M. Trezzi, O. Tsybakova, D. Turner, A. Vaglia, M.M. Results were similar for the subgroup of white patients (For immunologically confirmed hypersensitivity reaction, the HLA-B*5701 allele was associated with a positive predictive value of 47.9% and a negative predictive value of 100%.
and MediTech Media (S.R.) Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01.
They help the immune system to identify and respond to foreign substances, such as bacteria and viruses. Of the patients receiving abacavir, 72% were men, 84% were white, and 18% had not previously received antiretroviral therapy.
None of the 100 patients were carriers of HLA-B*5701. den Hollander, J.-M. Descamps, A. Devidas, P. Di Gregorio, G. Di Perri, D. Dockrell, P. Domingo, S. Echevarría, B. Elharrar, S. Esser, V. Estrada, A. Fakoya, G. Fätkenheuer, V. Faucherre, J. Fehr, G. Ferrea, C. Fontier Roussel, L. Force, G. Force, R. Fox, H. Furrer, M.J. Galindo Puerto, H. Gallais, J.-A. Mallal, Carosi, and Molina report receiving consulting fees, lecture fees, and grant support from GlaxoSmithKline; Dr. Mallal, being the sole shareholder of a company with a patent pending for HLA-B*5701 testing; Drs. ); GlaxoSmithKline, Research Triangle Park, NC (A.H.); and GlaxoSmithKline, Brentford, United Kingdom (N.F., D.T., A.B.